DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ceprotin (Protein C) - Summary

 
 



CEPROTIN SUMMARY

CEPROTIN [Protein C Concentrate (Human)] is manufactured from human plasma purified by a combination of filtration and chromatographic procedures, including a column of immobilized mouse monoclonal antibodies on gel beads. See WARNINGS/PRECAUTIONS: Transmission of Infectious Agents .

CEPROTIN is indicated for patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. CEPROTIN is indicated as a replacement therapy for pediatric and adult patients.


See all Ceprotin indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Ceprotin (Protein C)

Novel approach developed to visualize, measure protein complexes in tumors
Source: Lung Cancer News From Medical News Today [2015.01.19]
Cancer diagnosis and treatment decisions are often hampered by a lack of knowledge of the biological processes occurring within the tumor.

How a protein crucial to learning and memory works
Source: Autism News From Medical News Today [2015.01.09]
Researchers at Johns Hopkins have found out how a protein crucial to learning works: by removing a biochemical "clamp" that prevents connections between nerve cells in the brain from growing stronger.

In drug-resistant non-Hodgkin lymphomas, 'survival' protein may be a target
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.01.14]
Melbourne researchers have discovered that targeting a cell 'survival' protein could help treat some lymphomas, including those cancers with genetic defects that make them resistant to many existing...

Long-term data showing efficacy and safety of investigational cholesterol-lowering medication evolocumab announced
Source: Cholesterol News From Medical News Today [2014.11.20]
Amgen has announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication.

The inhibition of a mitochondrial fission protein shows promise as a potential treatment for Parkinson's disease
Source: Huntingtons Disease News From Medical News Today [2014.11.08]
A study led by a researcher from Plymouth University in the UK, has discovered that the inhibition of a particular mitochondrial fission protein could hold the key to potential treatment for...

more news >>

Published Studies Related to Ceprotin (Protein C)

Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. [2011.09]
Chronic wounds arising from orthopedic surgery present a major clinical challenge. Osteomyelitis may develop from polymicrobial infection, which can be unresponsive to treatment and lead to amputation...

A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. [2011.08]
OBJECTIVE: To investigate the association between markers of acute endothelial glycocalyx degradation, inflammation, coagulopathy, and mortality after trauma. BACKGROUND: Hyperinflammation and acute coagulopathy of trauma predict increased mortality. High catecholamine levels can directly damage the endothelium and may be associated with enhanced endothelial glycocalyx degradation, evidenced by high circulating syndecan-1... CONCLUSIONS: In trauma patients, high circulating syndecan-1, a marker of endothelial glycocalyx degradation, is associated with inflammation, coagulopathy and increased mortality.

Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. [2011.04.15]
RATIONALE: Patients with acute lung injury have impaired function of the lung surfactant system. Prior clinical trials have shown that treatment with exogenous recombinant surfactant protein C (rSP-C)-based surfactant results in improvement in blood oxygenation and have suggested that treatment of patients with severe direct lung injury may decrease mortality. OBJECTIVES: Determine the clinical benefit of administering an rSP-C-based synthetic surfactant to patients with severe direct lung injury due to pneumonia or aspiration... CONCLUSIONS: In this study, rSP-C-based surfactant was of no clinical benefit to patients with severe direct lung injury. The unexpected lack of improvement in oxygenation, coupled with the results of in vitro tests, suggest that the administered suspension may have had insufficient surface activity to achieve clinical benefit.

Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. [2011]
INTRODUCTION: There are no published data on the status of endogenous activated protein C (APC) in pulmonary embolism (PE), and no data on the effect of drotrecogin alfa (activated) (DAA) given in addition to therapeutic dose enoxaparin... CONCLUSIONS: In patients with acute submassive PE endogenous APC levels are low. DAA infusion enhances the inhibition of fibrin formation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00191724.

Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. [2011]
Chronic wounds arising from orthopedic surgery present a major clinical challenge. Osteomyelitis may develop from polymicrobial infection, which can be unresponsive to treatment and lead to amputation...

more studies >>

Clinical Trials Related to Ceprotin (Protein C)

Ceprotin Treatment Registry [Recruiting]

Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock. [Recruiting]
The purpose of this study is to investigate the effects on systemic hemodynamics, microcirculation and organ function of human Protein C concentrate in patients with sepsis and septic shock.

Activated Protein C and Corticosteroids for Human Septic Shock [Recruiting]
This study aims at comparing the efficacy and safety of recombinant human activated protein C to that of low dose of corticosteroids and at investigating the interaction between these drugs in the management of septic shock

Safety Evaluation of 3K3A-APC in Ischemic Stroke [Recruiting]
The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of multiple ascending intravenous doses of 3K3A-APC, a Recombinant Variant of Human activated protein C (APC), in in the treatment of acute ischemic stroke following treatment with recombinant tissue plasminogen activator (tPA).

Effect of APC and Epo on the Inflammatory Response During Sepsis [Recruiting]

more trials >>


Page last updated: 2015-01-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014